Trial · NCT00174915
Adverse events215
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 215
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea (Excluding Infective) | Gastrointestinal disorders | Febuxostat 80 mg QD | 16 | 267 | |
| other | Diarrhoea (Excluding Infective) | Gastrointestinal disorders | Febuxostat 120 mg QD | 19 | 269 | |
| other | Diarrhoea (Excluding Infective) | Gastrointestinal disorders | Febuxostat 240 mg QD | 18 | 134 | |
| other | Diarrhoea (Excluding Infective) | Gastrointestinal disorders | Allopurinol QD | 17 | 268 | |
| other | Diarrhoea (Excluding Infective) | Gastrointestinal disorders | Placebo QD | 11 | 134 | |
| other | Gastrointestinal & Abdominal Pains, Excluding Oral,Throat | Gastrointestinal disorders | Febuxostat 80 mg QD | 5 | 267 | |
| other | Gastrointestinal & Abdominal Pains, Excluding Oral,Throat | Gastrointestinal disorders | Febuxostat 120 mg QD | 7 | 269 | |
| other | Gastrointestinal & Abdominal Pains, Excluding Oral,Throat | Gastrointestinal disorders | Febuxostat 240 mg QD | 8 | 134 | |
| other | Gastrointestinal & Abdominal Pains, Excluding Oral,Throat | Gastrointestinal disorders | Allopurinol QD | 6 | 268 | |
| other | Gastrointestinal & Abdominal Pains, Excluding Oral,Throat | Gastrointestinal disorders | Placebo QD | 3 | 134 | |
| other | Nausea and Vomiting Symptoms | Gastrointestinal disorders | Febuxostat 80 mg QD | 11 | 267 | |
| other | Nausea and Vomiting Symptoms | Gastrointestinal disorders | Febuxostat 120 mg QD | 10 | 269 | |
| other | Nausea and Vomiting Symptoms | Gastrointestinal disorders | Febuxostat 240 mg QD | 8 | 134 | |
| other | Nausea and Vomiting Symptoms | Gastrointestinal disorders | Allopurinol QD | 6 | 268 | |
| other | Nausea and Vomiting Symptoms | Gastrointestinal disorders | Placebo QD | 5 | 134 | |
| other | Influenza Viral Infections | Infections and infestations | Febuxostat 80 mg QD | 11 | 267 | |
| other | Influenza Viral Infections | Infections and infestations | Febuxostat 120 mg QD | 13 | 269 | |
| other | Influenza Viral Infections | Infections and infestations | Febuxostat 240 mg QD | 7 | 134 | |
| other | Influenza Viral Infections | Infections and infestations | Allopurinol QD | 10 | 268 | |
| other | Influenza Viral Infections | Infections and infestations | Placebo QD | 6 | 134 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00174915/events